NCT04271735View on ClinicalTrials.gov

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
PsoriasisAtherosclerotic Cardiovascular DiseaseObesityDyslipidemiaCardiometabolic Diseases
Interventions
DIETARY_SUPPLEMENT

Niagen

Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.

OTHER

Placebo

Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT04271735 - Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis | Biotech Hunter | Biotech Hunter